Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
Therapy Name | ITI-1001 |
Synonyms | |
Therapy Description |
ITI-1001 is a DNA vaccine engineered to express peptides from the human cytomegalovirus proteins pp65, gB, and IE-1, which potentially results in enhanced antitumor immune response (PMID: 35651802). |
Drug Name | Trade Name | Synonyms | Drug Classes | Drug Description |
---|---|---|---|---|
ITI-1001 | ITI 1001|ITI1001 | ITI-1001 is a DNA vaccine engineered to express peptides from the human cytomegalovirus proteins pp65, gB, and IE-1, which potentially results in enhanced antitumor immune response (PMID: 35651802). |
Molecular Profile | Indication/Tumor Type | Response Type | Therapy Name | Approval Status | Evidence Type | Efficacy Evidence | References |
---|
Clinical Trial | Phase | Therapies | Title | Recruitment Status | Covered Countries | Other Countries |
---|---|---|---|---|---|---|
NCT05698199 | Phase I | ITI-1001 | Study to Evaluate the Safety, Tolerability, Immunogenicity and Preliminary Efficacy of ITI-1001 In Patients With Newly Diagnosed Glioblastoma (GBM) | Active, not recruiting | USA | 0 |